The current trends within the pharmaceutical industry portend a transition to an integrated industry, according to Pat McLaughlin of US broker Coopers & Lybrand; companies are changing from a focus on pharmaceuticals alone to health care in general.
He told those attending the Interphex conference on pharmaceutical manufacturing that previously the traditional three segments in the US health care market - providers, suppliers and payers - have had their own issues, but they will have to exploit their synergies in order to lower costs and improve quality.
Cost will remain one of the big drivers of the changing health care system well into the 21st century, he said, noting that the emerging opportunity for the supplier is to create a positive impact on the entire health care chain beyond that of its own costs, which represent only 8% of total health care expenditure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze